Skip to content

Type 2 diabetes — prevention

TL;DR — Intensive lifestyle programmes prevent or delay T2D in people with impaired glucose regulation: DPP reduced three-year incidence by 58% versus placebo, while metformin reduced it by 31% (Knowler 2002, PMID 11832527). The effect persists but attenuates over 15 years, and cumulative microvascular outcomes did not differ significantly across the original DPP groups overall (DPPOS 2015, PMID 26377054). Prevention labels are contested because fasting glucose, oral glucose tolerance and HbA1c define overlapping but non-identical “prediabetes” populations. Individual programmes work, but population incidence also reflects food systems, poverty, sleep, medications, pregnancy history and environmental exposure.

Who is at high risk

Marker/context Risk information Limitation
Impaired fasting glucose Hepatic-resistance dominant phenotype Misses isolated post-load hyperglycaemia
Impaired glucose tolerance Two-hour OGTT abnormality Poor reproducibility and inconvenient sampling
HbA1c 5.7–6.4% Longer-term glycaemic exposure Altered by erythrocyte biology and assay context
Prior gestational diabetes Strong life-course risk in women Follow-up is often fragmented (Kautzky-Willer 2023, PMID 36897358)
Family history/ancestry Captures inherited and shared environment Not a mechanism-specific test
BMI/waist/ectopic fat Major population-attributable risk Risk exists below obesity thresholds (GBD 2021 Diabetes Collaborators 2023, PMID 37356446)
Antipsychotic/glucocorticoid exposure Iatrogenic risk Baseline disease and indication confound estimates

The ADA diagnostic thresholds define increased-risk categories, but they should not be interpreted as a discrete biological disease boundary (ADA 2026, PMID 41358893).

Landmark prevention trials

Trial Population/intervention Diabetes incidence result Follow-up lesson
US DPP 3,234 high-risk adults; lifestyle, metformin or placebo Lifestyle −58%; metformin −31% over mean 2.8 years Benefits persist but converge with time (Knowler 2002, PMID 11832527)
DPPOS Long-term follow-up of DPP At 15 years, incidence reductions remained 27% lifestyle and 18% metformin vs original placebo No overall between-group microvascular difference (DPPOS 2015, PMID 26377054)
Finnish DPS Impaired glucose tolerance; lifestyle counselling Large reduction in progression Demonstrated transferability outside US DPP
Da Qing Cluster-randomised diet/exercise in China Durable prevention signal Long follow-up links prevention to later clinical outcomes

The DPP lifestyle target combined ≥7% weight loss with ≥150 minutes/week of physical activity. It was an intensive behavioural programme, not a simple advice leaflet (Knowler 2002, PMID 11832527).

What “prevention” means

Endpoint Strength Weakness
Biochemical diabetes diagnosis Early and feasible Can represent delay across a threshold rather than permanent avoidance
Medication-free normoglycaemia Clinically legible Less common and sensitive to test choice
Microvascular outcomes Patient-relevant Requires long follow-up and large samples
Cardiovascular events/mortality Most consequential Prevention trials are rarely powered for these outcomes
Healthy years/cost Policy-relevant Highly system-dependent

Delayed diagnosis is valuable because younger diagnosis predicts greater lifetime vascular risk (Nanayakkara 2021, PMID 33313987). Yet a programme that shifts diagnosis by two years should not be described as lifelong prevention without longer observation.

Lifestyle components

Component Evidence-based role Implementation issue
Weight loss Dominant mediator for many high-BMI participants Weight regain is common
Physical activity Improves insulin sensitivity independent of large weight loss Built environment and disability constrain access
Dietary pattern Enables energy deficit and diet quality No single universal macronutrient prescription
Sleep/circadian regularity Associated with metabolic risk Intervention-outcome evidence is less mature
Smoking cessation Reduces cardiovascular risk Short-term weight gain can complicate messaging
Postpartum follow-up Identifies high-risk prior GDM Care transitions are a recurrent failure point

Suboptimal diet was associated with a large modelled share of incident T2D across 184 countries, but the comparative-risk model cannot establish which policy package will work locally (O'Hearn 2023, PMID 37069363).

Metformin

Metformin’s preventive effect was smaller than intensive lifestyle overall in DPP, but relative effectiveness varied by baseline characteristics (Knowler 2002, PMID 11832527). Its advantages are low cost, long experience and oral dosing; limitations include gastrointestinal intolerance, vitamin B12 depletion with long exposure, renal-function constraints and the fact that some apparent prevention is pharmacologic masking of glycaemia.

At 15 years, original metformin assignment remained associated with an 18% lower diabetes incidence compared with original placebo, versus 27% for lifestyle (DPPOS 2015, PMID 26377054).

Weight-loss pharmacotherapy and the prevention boundary

Modern incretin trials in obesity frequently report fewer participants crossing HbA1c thresholds while receiving treatment. SELECT showed cardiovascular benefit in people with overweight/obesity and established cardiovascular disease but no diabetes at baseline (Lincoff 2023, PMID 37952131). These results blur obesity treatment and diabetes prevention, but on-treatment normoglycaemia is not equivalent to durable prevention after withdrawal.

Tirzepatide produces mean weight reductions approaching 21% at the highest dose in obesity trials (Jastreboff 2022, PMID 35658024). Whether long-term pharmacotherapy is best classified as prevention, chronic risk control or treatment of obesity is partly semantic; the clinically relevant endpoints are durability, adverse events, cardiovascular outcomes and access.

Population prevention

Lever Causal rationale Evidence gap
Food pricing/reformulation Changes exposure upstream Substitution and equity effects
Walkable environments Supports routine activity Long implementation horizon
Maternal health Interrupts intergenerational risk Few long-term randomised policy studies
Air-quality improvement PM2.5 burden is modelled Diabetes-specific policy effect uncertain (GBD Air Pollution Collaborators 2022, PMID 35809588)
Access to preventive care Enables screening and structured programmes Risk of medicalising large populations
Poverty reduction Addresses food, stress and care constraints Effects diffuse across many outcomes

High BMI accounted for an estimated 52.2% (95% UI 25.5–71.8) of global T2D DALYs, but prevention framed solely as individual weight control ignores the systems shaping exposure (GBD 2021 Diabetes Collaborators 2023, PMID 37356446).

Benefits beyond incidence

Lifestyle programmes improve weight, blood pressure, fitness and quality-of-life measures even when participants later cross the diabetes threshold. Conversely, Look AHEAD in established T2D improved weight and risk factors but did not reduce its primary cardiovascular composite, warning against assuming that metabolic surrogates guarantee hard outcomes (Look AHEAD 2022, PMID 35312758).

Harms and opportunity costs

  • Labelling can create anxiety, stigma and insurance consequences.
  • Screening low-risk populations produces false positives and repeat testing.
  • Intensive programmes can preferentially reach people with more time and resources.
  • Weight-centred messaging can reinforce blame (Speight 2024, PMID 38128969).
  • Metformin and anti-obesity medicines impose medication burden on people without diabetes.

Translating DPP into systems

Component Fidelity requirement Adaptable element
Risk selection Biochemical high-risk definition Local screening route
Weight/activity goals Measurable behavioural targets Diet and activity format
Contact intensity Sufficient coaching and feedback In-person, group or digital delivery
Maintenance Continued relapse prevention Community/primary-care ownership
Outcomes Diabetes incidence and harms Additional local equity/cost outcomes

Absolute benefit varies

Relative effects should not be applied uniformly. A person with higher short-term conversion risk obtains a larger absolute reduction from the same relative effect, while low-risk labelling exposes more people to burden for fewer prevented diagnoses.

Evaluation framework

Level Outcome
Individual Weight, glycaemia, activity, distress, adverse effects
Programme Reach, retention, incidence, cost
Equity Uptake and effect by income, ancestry, geography and disability
Population Age-standardised incidence and complication burden
Sustainability Effect after active support ends

Prevention versus early treatment

The boundary is partly diagnostic: identical energy-balance biology may be labelled prevention at HbA1c 6.4% and remission treatment at 6.5%. Research should therefore report continuous glycaemia and organ risk rather than only threshold crossing.

Cross-domain evidence crosswalk

These adjacent studies constrain interpretation of this page and make explicit where its conclusions depend on prevention, organ-outcome, remission, burden or implementation evidence.

Verified evidence anchor Connection
(Lean 2018, PMID 29221645) Lean MEJ, et al. Primary care-led weight management for remission. Lancet. 2018
(Lean 2019, PMID 30852132) Lean MEJ, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT trial. Lancet Diabetes Endocrinol. 2019
(Lean 2024, PMID 38423026) Lean MEJ, et al. Five-year follow-up of DiRECT. Lancet Diabetes Endocrinol. 2024
(Taylor 2016, PMID 30058916) Taylor R. Calorie restriction and reversal of type 2 diabetes. Expert Rev Endocrinol Metab. 2016
(Taylor 2021, PMID 33289165) Taylor R. Type 2 diabetes and remission: practical management guided by pathophysiology. J Intern Med. 2021;289:754-770
(Frías 2021, PMID 34170647) Frías JP, et al. Tirzepatide versus Semaglutide. N Engl J Med. 2021
(Garvey 2023, PMID 37385275) Garvey WT, et al. Tirzepatide for obesity in people with type 2 diabetes. Lancet. 2023
(Schauer 2017, PMID 28199805) Schauer PR, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes: 5-Year Outcomes. N Engl J Med. 2017
(Davies 2022, PMID 36148880) Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. Diabetes Care. 2022
(Seuring 2015, PMID 25787932) Seuring T, et al. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Pharmacoeconomics. 2015;33:811-831
(Afroz 2018, PMID 30558591) Afroz A, et al. Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries. BMC Health Serv Res. 2018;18:972

Landmark prevention programmes beyond DPP

Trial/follow-up Population and intervention Diabetes effect Longer-horizon inference
Finnish DPS 522 adults with IGT; individual diet/activity counselling 4-year cumulative incidence 11% vs 23%; relative reduction 58% At median seven years, incidence 4.3 vs 7.4/100 person-years; relative reduction 43%, including 36% post-intervention (Tuomilehto 2001, PMID 11333990; Lindström 2006, PMID 17098085)
DPP/DPPOS 3,234 high-risk US adults; lifestyle, metformin or placebo Original 2.8-year reductions 58% and 31% At ten years, cumulative incidence remained 34% lower for lifestyle and 18% lower for metformin (Knowler 2009, PMID 19878986)
IDPP-1 531 younger, leaner Asian Indian adults with IGT 3-year incidence 55.0% control, 39.3% lifestyle, 40.5% metformin, 39.5% combination Relative reductions 28.5%, 26.4% and 28.2%; no additive benefit; NNT 6.4–6.9 (Ramachandran 2006, PMID 16391903)
Da Qing 577 adults with IGT; clinic-randomised diet, exercise or both for six years 51% lower incidence during intervention (HR 0.49, 95% CI 0.33–0.73) 43% lower over 20 years (HR 0.57, 0.41–0.81), but CVD and mortality differences were nonsignificant at that point (Li 2008, PMID 18502303)

At 20 years, Da Qing reported severe retinopathy in 9.2% of intervention participants versus 16.2% of controls (HR 0.53, 95% CI 0.29–0.99), but no significant nephropathy or neuropathy difference (Gong 2011, PMID 21046360). This is evidence that delaying diabetes can change at least one downstream microvascular outcome; it is not proof that every prevention programme reduces every complication.

IDPP mechanistic follow-up found that progression reflected loss of secretion relative to insulin resistance and that lifestyle plus metformin did not outperform either alone (Snehalatha 2009, PMID 19587369). Analyses of coexisting fasting and post-load dysglycaemia reinforce that absolute conversion risk and intervention response depend on the baseline glycaemic phenotype (Ramachandran 2010, PMID 20519663).

Prediabetes is a risk state, not a uniform disease

Among 3,412 adults aged ≥71 years, regression to normoglycaemia or death was more common than progression to diabetes during 6.5 years, cautioning against importing middle-aged trial conversion rates into older populations (Rooney 2021, PMID 33555311). Conversely, women with prior gestational diabetes had high DPP conversion risk and substantial benefit from metformin and lifestyle, demonstrating that history can identify a higher-absolute-benefit subgroup (Ratner 2008, PMID 18826999).

Prevention claim Evidence for Evidence against overgeneralisation
Lifestyle effects persist Finnish DPS and DPPOS retain relative benefit after intensive phases (Lindström 2006, PMID 17098085; Knowler 2009, PMID 19878986) Intervention arms converge after counselling ends; cumulative delay is not permanent immunity
Metformin is a population solution Durable, inexpensive DPP benefit; strong gestational-diabetes subgroup signal (Ratner 2008, PMID 18826999) Smaller average effect than intensive lifestyle and heterogeneous absolute benefit
Weight loss is the active ingredient Dose-response meta-analysis links greater loss with more regression and less progression (Jayedi 2024, PMID 39222689) Fitness, diet quality, sleep and medication may act partly independently; mediation is not randomised
“Prediabetes” warrants treatment High-risk IGT trials show large absolute effects Older-adult cohorts show low short-term progression and substantial regression/mortality competing risk (Rooney 2021, PMID 33555311)

A 21-year randomised DPP follow-up found no statistically significant reduction in total, obesity-related or diabetes-related cancer with lifestyle or metformin, illustrating why plausible downstream benefits should not be asserted without endpoint evidence (Heckman-Stoddard 2025, PMID 40243198). Prevention success should therefore be reported as time without diabetes, adverse effects, treatment burden, equity and hard outcomes—not only a diagnostic threshold crossing.

Open questions

  • Which prediabetes definition selects people with the greatest absolute benefit from intervention rather than merely the highest conversion rate? (ADA 2026, PMID 41358893)
  • Do incretin-based prevention effects persist after discontinuation, and what endpoint should define success? (Jastreboff 2022, PMID 35658024; Riddle 2021, PMID 34462270)
  • Which population policies reduce incidence without increasing stigma or food insecurity? Attributable-risk models do not answer this (O'Hearn 2023, PMID 37069363; Speight 2024, PMID 38128969).
  • Can prevention programmes be adapted for early-onset risk while preserving efficacy across culture and socioeconomic context? (Xie 2022, PMID 36740855)

References

  1. Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. PMID 11832527
  2. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin over 15-year follow-up. Lancet Diabetes Endocrinol. 2015. PMID 26377054
  3. American Diabetes Association Professional Practice Committee. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026. PMID 41358893
  4. Nanayakkara N, et al. Impact of age at type 2 diabetes diagnosis on mortality and vascular complications. Diabetologia. 2021;64:275-287. PMID 33313987
  5. O'Hearn M, et al. Incident type 2 diabetes attributable to suboptimal diet in 184 countries. Nat Med. 2023;29:982-995. PMID 37069363
  6. GBD 2021 Diabetes Collaborators. Global burden of diabetes, 1990-2021, with projections to 2050. Lancet. 2023;402:203-234. PMID 37356446
  7. GBD 2019 Diabetes and Air Pollution Collaborators. Type 2 diabetes attributable to PM2.5 air pollution, 1990-2019. Lancet Planet Health. 2022;6:e586-e600. PMID 35809588
  8. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID 35658024
  9. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. PMID 37952131
  10. Look AHEAD Research Group. Effects of Intensive Lifestyle Intervention on All-Cause Mortality. Diabetes Care. 2022. PMID 35312758
  11. Riddle MC, et al. Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care. 2021. PMID 34462270
  12. Kautzky-Willer A, et al. Sex differences in type 2 diabetes. Diabetologia. 2023;66:986-1002. PMID 36897358
  13. Xie J, et al. Global burden of type 2 diabetes in adolescents and young adults. BMJ. 2022;379:e072385. PMID 36740855
  14. Speight J, et al. Bringing an end to diabetes stigma and discrimination. Lancet Diabetes Endocrinol. 2024. PMID 38128969
  15. Lean MEJ, et al. Primary care-led weight management for remission. Lancet. 2018. PMID 29221645
  16. Lean MEJ, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT trial. Lancet Diabetes Endocrinol. 2019. PMID 30852132
  17. Lean MEJ, et al. Five-year follow-up of DiRECT. Lancet Diabetes Endocrinol. 2024. PMID 38423026
  18. Taylor R. Calorie restriction and reversal of type 2 diabetes. Expert Rev Endocrinol Metab. 2016. PMID 30058916
  19. Taylor R. Type 2 diabetes and remission: practical management guided by pathophysiology. J Intern Med. 2021;289:754-770. PMID 33289165
  20. Frías JP, et al. Tirzepatide versus Semaglutide. N Engl J Med. 2021. PMID 34170647
  21. Garvey WT, et al. Tirzepatide for obesity in people with type 2 diabetes. Lancet. 2023. PMID 37385275
  22. Schauer PR, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes: 5-Year Outcomes. N Engl J Med. 2017. PMID 28199805
  23. Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. Diabetes Care. 2022. PMID 36148880
  24. Seuring T, et al. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Pharmacoeconomics. 2015;33:811-831. PMID 25787932
  25. Afroz A, et al. Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries. BMC Health Serv Res. 2018;18:972. PMID 30558591
  26. Tuomilehto J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350. PMID 11333990
  27. Lindström J, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention. Lancet. 2006;368:1673-1679. PMID 17098085
  28. Knowler WC, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677-1686. PMID 19878986
  29. Ramachandran A, et al. The Indian Diabetes Prevention Programme (IDPP-1). Diabetologia. 2006;49:289-297. PMID 16391903
  30. Snehalatha C, et al. Insulin secretion and sensitivity in the Indian Diabetes Prevention Programme-1. Diabetes Care. 2009;32:1796-1801. PMID 19587369
  31. Ramachandran A, et al. Prevention when fasting and postglucose dysglycaemia coexist. Diabetes Care. 2010;33:2164-2168. PMID 20519663
  32. Li G, et al. Long-term effect of lifestyle interventions in the China Da Qing Diabetes Prevention Study. Lancet. 2008;371:1783-1789. PMID 18502303
  33. Gong Q, et al. Long-term effects of lifestyle intervention on diabetes-related microvascular complications. Diabetologia. 2011;54:300-307. PMID 21046360
  34. Ratner RE, et al. Prevention of diabetes in women with a history of gestational diabetes. J Clin Endocrinol Metab. 2008;93:4774-4779. PMID 18826999
  35. Rooney MR, et al. Risk of Progression to Diabetes Among Older Adults With Prediabetes. JAMA Intern Med. 2021;181:511-519. PMID 33555311
  36. Jayedi A, et al. Lifestyle weight loss, regression to normoglycaemia and progression to type 2 diabetes. Am J Clin Nutr. 2024;120:1043-1052. PMID 39222689
  37. Heckman-Stoddard BM, et al. Metformin and lifestyle intervention on cancer incidence over 21 years. Cancer Prev Res. 2025;18:401-411. PMID 40243198